Vendela Parrow

Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress

Bonagas, Nadilly; Gustafsson, Nina M. S.; Henriksson, Martin; Marttila, Petra et al.

Part of NATURE CANCER, p. 156, 2022

• DOI for Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress
• Download full text (pdf) of Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress

Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Andersson, Claes; Selvin, Tove; Blom, Kristin; Rubin, Jenny et al.

Part of Scientific Reports, 2020

• DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
• Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Blom, Kristin; Eriksson, Jenny; Berglund, Malin; Jarvius, Malin et al.

Part of BMC Research Notes, 2019

• DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
• Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Blom, Kristin; Senkowski, Wojciech; Jarvius, Malin; Berglund, Malin et al.

Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017

• DOI for The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress

Bonagas, Nadilly; Gustafsson, Nina M. S.; Henriksson, Martin; Marttila, Petra et al.

Part of NATURE CANCER, p. 156, 2022

• DOI for Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress
• Download full text (pdf) of Pharmacological targeting of MTHFD2 suppresses acute myeloid leukemia by inducing thymidine depletion and replication stress

Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Andersson, Claes; Selvin, Tove; Blom, Kristin; Rubin, Jenny et al.

Part of Scientific Reports, 2020

• DOI for Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway
• Download full text (pdf) of Mebendazole is unique among tubulin-active drugs in activating the MEK-ERK pathway

Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

Blom, Kristin; Eriksson, Jenny; Berglund, Malin; Jarvius, Malin et al.

Part of BMC Research Notes, 2019

• DOI for Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition
• Download full text (pdf) of Mebendazole-induced M1 polarisation of THP-1 macrophages may involve DYRK1B inhibition

The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation

Blom, Kristin; Senkowski, Wojciech; Jarvius, Malin; Berglund, Malin et al.

Part of Immunopharmacology and immunotoxicology, p. 199-210, 2017

• DOI for The anticancer effect of mebendazole may be due to M1 monocyte/macrophage activation via ERK1/2 and TLR8-dependent inflammasome activation